What is the recommended next step after completing 60 Gy radiation for stage IIIB non‑small cell lung cancer?

Consolidation Immunotherapy After 60 Gy Radiation for Stage IIIB NSCLC

After completing 60 Gy radiation with concurrent chemotherapy for unresectable stage IIIB NSCLC, you must immediately test for EGFR mutations and initiate consolidation therapy: osimertinib 80 mg daily if EGFR exon 19 deletion or L858R mutation is present, or durvalumab 10 mg/kg IV every 2 weeks (or 1500 mg every 4 weeks) for up to 12 months if EGFR-negative. 1, 2

Immediate Next Steps

1. Molecular Testing (If Not Already Done)

• Test for EGFR exon 19 deletion and exon 21 L858R mutation using appropriately sensitive methods 1
• This testing is critical because it determines which consolidation therapy to use
• Do not delay—testing should be completed or results obtained immediately after completing chemoradiation

2. Assess Eligibility for Consolidation Therapy

Before initiating consolidation, confirm:

• Performance status 0-1 2
• No disease progression after definitive concurrent chemoradiation 2
• Patient completed platinum-based doublet chemotherapy concurrent with 60 Gy radiation 1

3. Choose Consolidation Therapy Based on EGFR Status

If EGFR Exon 19 Deletion or L858R Mutation Present:

• Osimertinib 80 mg orally once daily until disease progression 1, 2
• This is a Category 1 recommendation for stage III disease 2
• Do NOT use durvalumab in EGFR-mutated patients—oncogenic drivers like EGFR mutations are associated with reduced benefit from PD-1/PD-L1 inhibitors 2

If EGFR-Negative (No Exon 19 Deletion or L858R Mutation):

• Durvalumab 10 mg/kg IV every 2 weeks OR 1500 mg every 4 weeks for up to 12 months (for patients ≥30 kg body weight) 1, 2
• This is a Category 1 recommendation for stage III disease 2
• Based on the landmark PACIFIC trial showing 5-year overall survival of 42.9% 3

Critical Timing Considerations

• Start consolidation therapy within 1-6 weeks after completing chemoradiation (standard practice based on PACIFIC trial design)
• Do not give additional chemotherapy cycles after radiation if using durvalumab or osimertinib 2
• If sequential (rather than concurrent) chemoradiation was used, osimertinib or durvalumab can still be considered based on molecular testing 2

Important Contraindications and Caveats

For Durvalumab:

• Contraindications include:
  • Active or previously documented autoimmune disease 2
  • Current use of immunosuppressive agents 2
• Be prepared to manage immune-related adverse events per NCCN Guidelines for Management of Immunotherapy-Related Toxicities 2

For Osimertinib:

• Avoid administering TKI in close temporal proximity to immunotherapy due to increased toxicity risk 2
• If patient previously received immunotherapy, allow appropriate washout period

What NOT to Do

• Do not routinely offer postoperative radiotherapy if surgical resection was performed 1
• Do not give additional consolidation chemotherapy after radiation if using durvalumab or osimertinib 2
• Do not use durvalumab in EGFR-mutated patients—this is explicitly excluded from guidelines 1, 2
• Do not delay molecular testing—this is time-sensitive for optimal outcomes

Algorithm Summary

Stage IIIB NSCLC → 60 Gy + concurrent chemo completed
↓
Check: PS 0-1? No progression? → If NO, supportive care/clinical trial
↓ If YES
EGFR testing (if not done)
↓
├─ EGFR exon 19 del or L858R → Osimertinib 80 mg daily (Category 1)
│
└─ EGFR-negative → Durvalumab every 2-4 weeks × 12 months (Category 1)

The evidence strongly supports this approach, with both ASCO 1 and NCCN 2 2024-2025 guidelines providing Category 1 (highest level) recommendations for these consolidation strategies based on robust clinical trial data showing significant survival improvements.